Exparel
Drug Pain Management
NDC 65250-266-20
General payments
$10,511,902
Research payments
$10,026,447
Through program year 2020, $10,511,902 in general payments and $10,026,447 in research payments were reported against Exparel (Pain Management).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | General | $3,256,182 | 3,909 |
| 2020 | Research | $5,612,548 | 221 |
| 2019 | General | $7,255,720 | 10,863 |
| 2019 | Research | $4,413,899 | 249 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.
The top 5 of 87 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of general payments naming this product in 2020 where a state was reported.
Records
14,772 general · 470 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.